Zimmer Biomet Holdings (ZBH) Cash & Equivalents (2009 - 2026)

Zimmer Biomet Holdings' Cash & Equivalents history runs 18 years deep, the most recent figure standing at $424.2 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 69.36% year-over-year to $424.2 million in Q1 2026; TTM through Mar 2026 was $424.2 million, a 69.36% decrease from a year earlier, with the FY2025 full-year figure at $591.9 million, up 12.64% from the prior year.
• Cash & Equivalents declined to $424.2 million in Q1 2026 per ZBH's latest filing, from $591.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $1.4 billion in Q1 2025 and bottomed at $292.1 million in Q3 2023.
• The 5-year median for Cash & Equivalents is $424.2 million (2026), against an average of $544.6 million.
• Across the five-year window, Cash & Equivalents surged 252.29% in 2025 and sank 69.36% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $375.7 million in 2022, then climbed by 10.67% to $415.8 million in 2023, then rose by 26.38% to $525.5 million in 2024, then climbed by 12.64% to $591.9 million in 2025, then decreased by 28.33% to $424.2 million in 2026.
• Per Business Quant, the three latest ZBH Cash & Equivalents figures stand at $424.2 million (Q1 2026), $591.9 million (Q4 2025), and $1.3 billion (Q3 2025).